This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Miesbach W, Pasi KJ, Pipe SW, et al. Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU. Haemophilia 2021; 27(4): 511–514. doi: 10.111/hae.14309.MiesbachWPasiKJPipeSWEvolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU202127451151410.111/hae.14309Open DOISearch in Google Scholar
Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres – A need for re-evaluation of infrastructure and comprehensive care: A joint publication of EAHAD and the EHC. Haemophilia 2021; 27(6): 967–973. doi: 10.1111/hae.14420.MiesbachWChowdaryPCoppensMDelivery of AAV-based gene therapy through haemophilia centres – A need for re-evaluation of infrastructure and comprehensive care: A joint publication of EAHAD and the EHC202127696797310.1111/hae.1442034553460Open DOISearch in Google Scholar
EUHANET. European guidelines for the certification of haemophilia centres. 2013. Available from http://www.euhanet.org/docs/Euhanet-European_guidelines_for_the_certification_of_Haemophilia_Centres_2013.pdf (accessed 30 August 2022).EUHANET2013Available from http://www.euhanet.org/docs/Euhanet-European_guidelines_for_the_certification_of_Haemophilia_Centres_2013.pdf (accessed 30 August 2022).Search in Google Scholar
Miesbach W, Baghaei F, Boban A, et al. Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and the EHC. Haemophilia 2022; 28: e86–88. doi: 10.1111/hae.14546.MiesbachWBaghaeiFBobanAGene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and the EHC202228e868810.1111/hae.1454635263819Open DOISearch in Google Scholar
Miesbach W, Barcenilla SG, Golan G, Lobet S. Implications of haemophilia gene therapy for changing role of the multidisciplinary team. Haemophilia 2022; 28(1): e12–e14. doi: 10.1111/hae.14440.MiesbachWBarcenillaSGGolanGLobetSImplications of haemophilia gene therapy for changing role of the multidisciplinary team2022281e12e1410.1111/hae.14440929842934668286Open DOISearch in Google Scholar
Peyvandi F, Lillicrap D, Mahlangu J, et al. Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Res Pract Thromb Haemost 2020; 4(4): 644–651. doi: 10.1002/rth2.12326.PeyvandiFLillicrapDMahlanguJHemophilia gene therapy knowledge and perceptions: Results of an international survey20204464465110.1002/rth2.12326729267332548564Open DOISearch in Google Scholar
Fletcher S, Jenner K, Holland M, Khair K. Expectation and loss when gene therapy for haemophilia is not an option: an Exigency sub-study. 2022 [Manuscript submitted for publication]FletcherSJennerKHollandMKhairK2022[Manuscript submitted for publication]Search in Google Scholar
Wang M, Negrier C, Driessler F, Goodman C, Skinner ME. The hemophilia gene therapy patient journey: questions and answers for share decision-making. Patient Prefer Adherence 2022; 16: 1439–1447. doi: 10.2147/PPA.S355627.WangMNegrierCDriesslerFGoodmanCSkinnerMEThe hemophilia gene therapy patient journey: questions and answers for share decision-making2022161439144710.2147/PPA.S355627919157735707346Open DOISearch in Google Scholar
Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis 2022; 17: 155. doi: 10.1186/s13023-022-02256-2.FletcherSJennerKPembrokeLHollandMKhairKThe experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study20221715510.1186/s13023-022-02256-2898174735379267Open DOISearch in Google Scholar
Woollard L, Gorman R, Rosenfelt DJ. Improving patient informed consent for haemophilia gene therapy: the case for change. Ther Adv Rare Dis 2021; 2: 1–16. doi: 10.1177/26330040211047244.WoollardLGormanRRosenfeltDJImproving patient informed consent for haemophilia gene therapy: the case for change2021211610.1177/26330040211047244Open DOISearch in Google Scholar
Miesbach W, O'Mahony B, Key NS, Makris M How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019; 25(4): 545–557. doi: 10.1111/hae.13769.MiesbachWO'MahonyBKeyNSMakrisMHow to discuss gene therapy for haemophilia? A patient and physician perspective201925454555710.1111/hae.13769685220731115117Open DOISearch in Google Scholar
Kaczmarek R, Pierce GF, Noone D, et al. Eliminating Panglossian thinking in development of AAV therapeutics. Mol Ther 2021; 29(12): 3325–3327. doi: 10.1016/j.ymthe.2021.10.025.KaczmarekRPierceGFNooneDEliminating Panglossian thinking in development of AAV therapeutics202129123325332710.1016/j.ymthe.2021.10.025863616634758292Open DOISearch in Google Scholar
Nossair F, Thornburg CD. The role of patient and healthcare professionals in the era of new haemophilia treatments in developed and developing countries. Ther Adv Hematol 2018; 9(8): 239–249. doi: 10.1177/2040620718784830.NossairFThornburgCDThe role of patient and healthcare professionals in the era of new haemophilia treatments in developed and developing countries20189823924910.1177/2040620718784830611675730181844Open DOISearch in Google Scholar
Konkle BA, Coffin D, Pierce GF, et al. World Federation of Hemophilia Gene Therapy Registry. Haemophilia 2020; 26(4): 563–564. doi: 10.1111/hae.14015.KonkleBACoffinDPierceGFWorld Federation of Hemophilia Gene Therapy Registry202026456356410.1111/hae.14015894492232462720Open DOISearch in Google Scholar
Hart DP, Branchford BR, Hendry S, et al. Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet J Rare Dis 2021; 16: 189. doi: 10.1186/s13023-020-01555-w.HartDPBranchfordBRHendrySOptimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study20211618910.1186/s13023-020-01555-w808283633910590Open DOISearch in Google Scholar
Sidonio RF, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev 2021; 47: 100759. doi: 10.1016/j.blre.2020.100759.SidonioRFPipeSWCallaghanMUValentinoLAMonahanPECroteauSEDiscussing investigational AAV gene therapy with hemophilia patients: A guide20214710075910.1016/j.blre.2020.10075933183859Open DOISearch in Google Scholar
Valentino LA, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178.ValentinoLABlanchetteVNegrierCPersonalising haemophilia management with shared decision making202181697910.17225/jhp00178Open DOISearch in Google Scholar
Fletcher S, Jenner K, Holland M, Chaplin S, Khair K. An exploration of why men with severe haemophilia might not want gene therapy: The exigency study. Haemophilia 2021; 27(5): 760–768. doi: 10.1111/hae.14378.FletcherSJennerKHollandMChaplinSKhairKAn exploration of why men with severe haemophilia might not want gene therapy: The exigency study202127576076810.1111/hae.1437834265145Open DOISearch in Google Scholar
AHRQ. The SHARE approach: a model for shared decision making. Last reviewed September 2020. Available from https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html (accessed 31 August 2022).AHRQLast reviewed September 2020. Available from https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html (accessed 31 August 2022).Search in Google Scholar
Pipe SW, Reddy KJ, Chowdary P. Gene therapy: Practical aspects of implementation. Haemophilia 2022; 28 (Suppl 4): 44–52. doi: 10.1111/hae.14545.PipeSWReddyKJChowdaryPGene therapy: Practical aspects of implementation202228Suppl 4445210.1111/hae.14545932408935521727Open DOISearch in Google Scholar
Arruda VR, Samelson-Jones BJ. Obstacles and future of gene therapy for hemophilia. Expert Opin Orphan Drugs 2015; 3(9): 997–1010. doi: 10.1517/21678707.2015.1069169.ArrudaVRSamelson-JonesBJObstacles and future of gene therapy for hemophilia201539997101010.1517/21678707.2015.1069169Open DOISearch in Google Scholar
Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood 2021; 138(11): 923–931. doi: 10.1182/blood.LeebeekFWGMiesbachWGene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues20211381192393110.1182/bloodOpen DOISearch in Google Scholar
Miesbach W, Klamroth R. The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients. Patient Prefer Adherence 2020; 14: 767–770. doi: 10.2147/PPA.S239810.MiesbachWKlamrothRThe patient experience of gene therapy for hemophilia: qualitative interviews with trial patients20201476777010.2147/PPA.S239810718485832368018Open DOISearch in Google Scholar
Batty P, Lillicrap D. Hemophilia gene therapy: Approaching the first licensed product. Hemasphere 2021; 5(3): e540. doi: 10.1097/HS9.0000000000000540.BattyPLillicrapDHemophilia gene therapy: Approaching the first licensed product202153e54010.1097/HS9.0000000000000540788645833604517Open DOISearch in Google Scholar
Bolz-Johnson M, Meek J, Hoogerbrugge N. “Patient Journeys”: improving care by patient involvement. Eur J Hum Genet 2020; 28: 141–143. doi: 10.1038/s41431-019-0555-6.Bolz-JohnsonMMeekJHoogerbruggeN“Patient Journeys”: improving care by patient involvement20202814114310.1038/s41431-019-0555-6697460031801983Open DOISearch in Google Scholar